Fusion proteins and use thereof for preparing hepatitis C vaccines

摘要

An immunogenic fusion protein includes at least, on the C-terminal side, a first peptide composed of the S protein deleted of the transmembrane domain thereof located at the N-terminal end thereof, of a hepatitis B virus (HBV) isolate, and on the N-terminal side, a second peptide composed of the transmembrane domain and of the ectodomain of at least one envelope protein of a hepatitis C virus (HCV) isolate. A hybrid nucleic acid molecule encoding the fusion protein, and a vector including the hybrid nucleic acid molecule, a subviral particle including the fusion protein, an immunogenic composition including at least the fusion protein, or at least the hybrid nucleic acid molecule, or at least the subviral particle, and a cell line for the production of the fusion protein, or of the hybrid nucleic acid molecule, or of the subviral particle are described.

主权项

1. An immunogenic fusion protein comprising the following two peptides:
a) at the C-terminal side of the fusion protein, a first peptide consisting of the amino acid sequence of the S protein of human hepatitis B virus (HBV), wherein the S protein is deleted of the transmembrane domain located at the N-terminal thereof, and b) at the N-terminal side of the fusion protein, a second peptide consisting of the amino acid sequence of the transmembrane domain and the ectodomain of an envelope protein of hepatitis C virus (HCV), said envelope protein being selected from the group consisting of protein E1, protein E2, and a fusion peptide comprising protein E1 and protein E2.